CD55 antibody | 67
Filter by Application:F C IF Reset
Mouse anti Human CD55
- Product Type
- Monoclonal Antibody
|Mouse anti Human CD55 antibody, clone 67 recognizes the human CD55 cell surface antigen, a GPI linked molecule also known as decay accelerating factor (DAF). CD55 is expressed by a wide range of cell types.
CD55 is the complement regulatory protein, decay accelerating factor (DAF) (Lublin and Atkinson 1989). Human CD55 is a ~70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O-glycans, and also on N-glycan. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries the
DAF has a wide distribution on cells in non-haematopoietic tissues, particularly epithelium and is found at the fetal-maternal interface in placenta (Holmes et al. 1990 and Yang et al. 2009). Soluble forms of DAF are found, for example, in plasma, saliva and urine (
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% sodium azide (NaN3)
- Carrier Free
- K562 cells
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- For research purposes only
- 12 months from date of despatch
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen||1/100||1/1000|
- Flow Cytometry
- Use 10μl of the suggested working dilution to label 106 cells in 100μl. Please note: Bio-Rad do not recommend the use of this reagent to stain erythrocytes
- Histology Positive Control Tissue
- Human tonsil
References for CD55 antibody
Hadam, M.R. (1989) In Leucocyte Typing IV: White Cell Differentiation Antigens.
Edited by Knapp, W. et al. Oxford University Press pp 694-697.
Holmes, C.H. et al. (1990) Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.
J Immunol. 144 (8): 3099-105.
O'Brien, D.P. et al. (2009) Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor.
J Biol Chem. 283: 23922-30.
Kraan, M.C. et al. (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.
Ann Rheum Dis. 63: 483-8.
van Holten, J. et al. (2005) A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
Ann Rheum Dis. 64 (1): 64-9.
Yang, P. et al. (2009) Expression and modulation of RPE cell membrane complement regulatory proteins.
Invest Ophthalmol Vis Sci. 50: 3473-81.
van de Sande, M.G. et al. (2011) Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase.
Ann Rheum Dis. 70: 772-7.
Araten, D.J. et al. (2005) A quantitative measurement of the human somatic mutation rate.
Cancer Res. 65: 8111-7.
View The Latest Product References
Mo, B. et al. (2006) ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium.
Biol Reprod. 75: 387-94.
Vos, K. et al. (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Arthritis Rheum. 56 (3): 772-8.
de Launay, D. et al. (2010) Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis.
Am J Pathol. 177: 3010-24.
Gheorghe, K.R. et al. (2011) Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
PLoS One. ;6: e16378.
Abreu, J.R. et al. (2009) The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.
Arthritis Res Ther.11(4):R121.
Thurlings, R.M. et al. (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
Ann Rheum Dis. 67 (7): 917-25.
Edginton S et al. (2016) Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium.
J Rheumatol. 43 (5): 846-54.
- Entrez Gene
- GO Terms
- GO:0005576 extracellular region
- GO:0005887 integral to plasma membrane
- GO:0005625 soluble fraction
- GO:0006958 complement activation, classical pathway
- GO:0007204 elevation of cytosolic calcium ion concentration
- GO:0031225 anchored to membrane
- GO:0045087 innate immune response
- GO:0045121 membrane raft
- GO:0045730 respiratory burst
- View More GO Terms
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up